Resources Repository
-
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | North America -
ReviewPublication 2012Modeling Preventative Strategies Against HPV-Related Disease in Developed Countries
This review article is part of a special supplement on “Comprehensive Control of HPV Infections …
This review article is part of a special supplement on “Comprehensive Control of HPV Infections and Related Diseases.” At the time of its writing, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females had been introduced in most developed countries, supported by modeled evaluations that had almost universally found vaccination of pre-adolescent females to be cost-effective. Vaccination of pre-adolescent males had been shown to be cost-effective at a cost per vaccinated individual of ~US$400-500 if…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Social Determinants | Health Systems | Global -
ReviewPublication 2011Dynamic Microsimulation Models for Health Outcomes: A Review
This review article presents an overview of microsimulation modeling, focusing on the development and application …
This review article presents an overview of microsimulation modeling, focusing on the development and application of these models for health policy questions. Microsimulation models for health outcomes simulate individual event histories associated with key components of a disease process; these simulated life histories can be aggregated to estimate population-level effects of treatment on disease outcomes and the comparative effectiveness of treatments. The authors argue that methodological improvements in modeling approaches have been slowed by the…
Microsimulation | Calibration/Validation | Health/Medicine | Health Outcomes -
ReviewPublication 2010Validation of Population-Based Disease Simulation Models: A Review
This article develops a framework for validating population-based chronic disease simulation models, and reviews the …
This article develops a framework for validating population-based chronic disease simulation models, and reviews the principles and methods for such models. While computer simulation models are used increasingly to support public health research and policy, questions about their quality persist. Based on the review, the authors formulated a set of recommendations for gathering evidence of model credibility. They find that evidence of model credibility derives from examining: 1) the process of model development, 2) the…
Mathematical Models | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Social Determinants -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Global -
ReviewPublication 1982Decision Analysis: An Overview
This article, written for the non-decision analyst, describes what decision analysis is, what it can …
This article, written for the non-decision analyst, describes what decision analysis is, what it can and cannot do, why one should care to do this, and how one does it. Keeney describes decision analysis as "a formalization of common sense for decision problems which are too complex for informal use of common sense." He provides a more technical definition also, describing decision analysis as "a philosophy, articulated by a set of logical axioms, and a methodology…
Decision Analysis | Health/Medicine | Business/Industry | Decision Theory | Preferences/Values | Policy/Regulation | Economics/Finance | Energy/Engineering | Government/Law | Military/Defense | Science/Technology -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | North America -
ReviewPublication 2023Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: Methodological Review
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms …
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms in Parkinson’s disease in studies published post-2010. Methods included a systematic literature search using databases such as PubMed, EconLit, Cochrane, and several UK National Health Service databases, covering March 2010 to July 2022. The quality of the identified studies was assessed using a checklist from the German Scientific Working Group. Results showed that 20 studies were evaluated, most employing Markov…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Chronic Disease/Risk -
ReviewPublication 2023Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: Systematic Review
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) …
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) in at-risk adult populations. Methods included searching PubMed and Scopus for articles published between January 2016 and May 2022. The first reviewer screened all articles, while a second reviewer independently validated a random 10% sample. Discrepancies were resolved through discussion, with a third reviewer involved if necessary. Costs were standardized to 2021 euros. Reporting quality was evaluated using the CHEERS…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Chronic Disease/Risk